MYC inhibits migration of lung cancer cell lines by down-regulating AKR1C1 expression

doi:10.16352/j.issn.1001-6325.2024.12.1621

Abstract

Abstract: Objective To explore the role of MYC in lung cancer cell migration and reveal the mechanism affecting migration. Methods siRNA MYC or pRK5-MYC plasmid was transfected into lung cancer cells A549. Cell migration was examined by wound healing assay. The mRNA expression of candidate genes AKR1C1 and AKR1C3 was detected by fluorescence quantitative PCR. Dual luciferase reporting assay and chromatin immunoprecipitation assay (ChIP) verified the transcriptional regulation of target genes by MYC. A549 cells were transfected with MYC and AKR1C1 siRNA or pRK5-MYC and pRK5-AKR1C1 at the same time. Wound healing assay and Transwell were used to examine cell migration and cell invasion respectively. Results Knockdown MYC in A549 cells promoted cell migration, and over-expression of MYC inhibited cell migration. The level of protein and mRNA of AKR1C1 was significantly increased(P＜0.01) after knockdown MYC. The ChIP assay showed that MYC binded to the response element (RE) of AKR1C1. Compared with control plasmids, MYC induced the expression of luciferase in RE-containing plasmids. Decreased expression of AKR1C1 inhibited the invasion and migration of lung cancer cells(P＜0.05). AKR1C1 reduced cell invasion and migration caused by MYC loss(P＜0.05). Conclusions MYC might inhibit cancer cell migration by inhibiting AKR1C1 expression.

Key words: lung cancer, cell migration, MYC, AKR1C1

CLC Number:

JIA Kun, ZHOU Yanyan. MYC inhibits migration of lung cancer cell lines by down-regulating AKR1C1 expression[J]. Basic & Clinical Medicine, 2024, 44(12): 1621-1627.

References

[1]Massó-Vallés D, Beaulieu ME, Soucek L. MYC, MYCL, and MYCN as therapeutic targets in lung cancer[J]. Expert Opin Ther Targets, 2020, 24:101-114.
[2]Wei X, Wei Z, Li Y, et al. AKR1C1 contributes to cervical cancer progression via regulating TWIST1 expression[J]. Biochem Genet, 2021, 59:516-530.
[3]Zhu H, Chang LL, Yan FJ, et al. AKR1C1 activates STAT3 to promote the metastasis of non-small cell lung cancer[J]. Theranostics, 2018, 8:676-692.
[4]Lee HY, Cha J, Kim SK, et al. c-MYC drives breast cancer metastasis to the brain, but promotes synthetic lethality with TRAIL[J]. Mol Cancer Res, 2019, 17:544-554.
[5]Li ZY, Xie Y, Deng M, et al. c-Myc-activated intronic miR-210 and lncRNA MIR210HG synergistically promote the metastasis of gastric cancer[J]. Cancer Lett, 2022, 526:322-334.
[6]Liu H, Radisky DC, Yang D, et al. MYC suppresses cancer metastasis by direct transcriptional silencing of αv and β3 integrin subunits[J]. Nat Cell Biol, 2012, 14:567-574.
[7]Ma X, Huang J, Tian Y, et al. Myc suppresses tumor invasion and cell migration by inhibiting JNK signaling[J]. Oncogene, 2017, 36:3159-3167.
[8]Zhao M, Jiang P, Du W. MYC retards cancer cell migration through suppressing fibronectin expression[J]. Sci Bull (Beijing), 2019, 64:715-717.
[9]Chu X, He S, Liu Y, et al. Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): functions, regulation, and structural insights of inhibitors[J]. Chem Biol Interact, 2022, 351:109746. doi: 10.1016/j.cbi.2021.109746.
[10]Ji Q, Aoyama C, Chen PK, et al. Localization and altered expression of AKR1C family members in human ovarian tissues[J]. Mol Cell Probes, 2005, 19:261-266.
[11]Paullin T, Powell C, Menzie C, et al. Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses[J]. PLoS One, 2017, 12: e0182930. doi: 10.1371/journal.pone.0182930.
[12]Huang J, Jiang W, Tong X, et al. Identification of gene and microRNA changes in response to smoking in human airway epithelium by bioinformatics analyses[J]. Medicine (Baltimore), 2019, 98: e17267. doi: 10.1097/MD.0000000000017267.
[13]Fukumoto S, Yamauchi N, Moriguchi H, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas[J]. Clin Cancer Res, 2005, 11:1776-1785.
[14]Chang LL, Lu PH, Yang W, et al. AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1α and metabolic reprogramming[J]. Transl Oncol, 2022, 20:101421. doi: 10.1016/j.tranon.2022.101421.

[1]	ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan. Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
[2]	CAO Qingwen, QI Lin, YU Bo, TIAN Chenchen, YUAN Haining, WANG Yue. Salidroside promotes proliferation and migration of human vascular endothelial cell line EA.hy926 [J]. Basic & Clinical Medicine, 2024, 44(7): 925-930.
[3]	CAO Chenxin, TANG Hui, GENG Ruixuan, GUO Fuping, BAI Chunmei, WANG Yingyi, LI Taisheng. Correlation between circulating CD4⁺CD45RA⁺CD62L⁺ T cells and prognosis of metastatic non-small cell lung cancer treated with EGFR-TKI [J]. Basic & Clinical Medicine, 2024, 44(5): 658-664.
[4]	JIA Anna, GUO Jinxin, ZHANG Xuan, ZHAN Shijia, YU Yongbo, GUO Yongli, CHANG Yan. Regulation of TMEFF1 on proliferation of neuroblastoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(5): 637-644.
[5]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[6]	LU Kai, LU Jianju, GUO Wenli, HUANG Jianqi, LI Zhihua. lncRNA VIM-AS5 expression and its effect on proliferation and migration of human breast cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 447-453.
[7]	ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin. Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib [J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
[8]	JIA Anna, ZHAN Shijia, ZHANG Xuan, GUO Jinxin, YU Yongbo, GUO Yongli, CHANG Yan. Regulatory effect of C12ORF66 on viability of MYCN amplified high-risk neuroblastoma cells [J]. Basic & Clinical Medicine, 2024, 44(3): 288-294.
[9]	LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai. Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 247-251.
[10]	DING Fei, WANG Sa, HUANG Changxin. Serum CA211 level and NK cell number are associated with prognosis of patients with non-small cell lung cancer [J]. Basic & Clinical Medicine, 2024, 44(2): 180-184.
[11]	ZHANG Jinfang, ZHONG Mingyan, YANG Quan, FENG Bei, LI Xingdong. Down-regulation of ATM/hnRNPK signaling reduces adriamycin resistance of myeloid leukemia [J]. Basic & Clinical Medicine, 2024, 44(12): 1638-1643.
[12]	. Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC [J]. Basic & Clinical Medicine, 2024, 44(10): 1383-1387.
[13]	YAN Chenhong, JIN Er. Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer [J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461.
[14]	ZHANG Xiaowan, KANG Xia, YAO Xiaoying, XIE Fang, LI Ying. Silencing SF3B1 promotes apoptosis and inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2023, 43(8): 1265-1270.
[15]	LIN Yingxue, CUI Haipeng, WANG Aiguo, YAO Yinhui, ZHAO Juan. Rapamycin alleviates hepatocellular carcinoma progressing in transgenic mice [J]. Basic & Clinical Medicine, 2023, 43(8): 1241-1246.